3 Einträge gefunden

1. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

   1. Weisel, Katja
   2. Nooka, Ajay K
   3. Terpos, Evangelos
   4. Spencer, Andrew
   5. Goldschmidt, Hartmut
   6. Dirnberger, Franziska
   7. DeCosta, Lucy

   2022 - Forschungsinformationssystem des UKE
2. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

   1. Weisel, Katja
   2. Mateos, Maria-Victoria
   3. Gay, Francesca
   4. Delforge, Michel
   5. Cook, Gordon
   6. Szabo, Zsolt
   7. Desgraz, Renaud

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

   1. Weisel, Katja
   2. Majer, Istvan
   3. DeCosta, Lucy
   4. Oriol, Albert
   5. Goldschmidt, Hartmut
   6. Ludwig, Heinz
   7. Campioni, Marco

   2020 - Forschungsinformationssystem des UKE